Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer

Medical Hypotheses

Volumn 67, Issue 4, 2006, Pages 744-746

  Aksoy, Sercan ^a   Aksoy, Hatice ^a   Harputluoglu, Hakan ^a   Kilickap, Saadettin ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; CORONARY ARTERY DISEASE; HUMAN; HYPERTENSION; OBESITY; PRIORITY JOURNAL; PROGNOSIS;

ANGIOGENESIS INDUCING AGENTS; ANTINEOPLASTIC AGENTS; COMORBIDITY; DISEASE MANAGEMENT; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 33745939514     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.04.033     Document Type: Article

References (10)

1. Janssen-Heijnen M.L., Houterman S., Lemmens V.E., Louwman M.W., Maas H.A., and Coebergh J.W. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55 3 (2005) 231-240
2. Silha J.V., Krsek M., Sucharda P., and Murphy L.J. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 29 11 (2005) 1308-1314
3. Freestone B., Chong A.Y., Lim H.S., Blann A., and Lip G.Y. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?. Ann Med 37 5 (2005) 365-372
4. Lim H.S., Blann A.D., Chong A.Y., Freestone B., and Lip G.Y. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 27 12 (2004) 2918-2924
5. Belgore F.M., Blann A.D., Li-Saw-Hee F.L., Beevers D.G., and Lip G.Y. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 87 6 (2001) 805-807
6. Nadar S.K., Blann A.D., and Lip G.Y. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Intern Med 256 4 (2004) 331-337
7. Rosen L.S. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 10 6 (2005) 382-391
8. Lee K.W., Lip G.Y., and Blann A.D. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110 16 (2004) 2355-2360
9. Alber H.F., Frick M., Dulak J., Dorler J., Zwick R.H., Dichtl W., et al. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart 91 3 (2005) 365-366
10. Alber H.F., Dulak J., Frick M., Dichtl W., Schwarzacher S.P., Pachinger O., et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol 39 12 (2002) 1951-1955